Research progress of FAPI PET/CT in the diagnosis of malignant liver tumors

Malignant liver tumors have a high incidence and mortality rate. Therefore, it is of great significance to promptly learn about tumor advancement status through relevant examinations for patients' follow-up, diagnosis, and therapy as well as the improvement of the five-year survival rate. The p...

Full description

Saved in:
Bibliographic Details
Published inZhonghua gan zang bing za zhi Vol. 31; no. 6; p. 664
Main Authors Zhang, X Y, Han, W, Lyu, Z H, Zhao, H Y, Fu, P, Zhao, C J
Format Journal Article
LanguageChinese
Published China 20.06.2023
Subjects
Fibroblast activator protein inhibitor
Hepatocellular carcinoma
Metastatic liver cancer
F-deoxyglucose
Positron emission tomography and computed tomography
Intrahepatic cholangiocarcinoma
Online AccessGet more information

Cover

More Information
Summary:Malignant liver tumors have a high incidence and mortality rate. Therefore, it is of great significance to promptly learn about tumor advancement status through relevant examinations for patients' follow-up, diagnosis, and therapy as well as the improvement of the five-year survival rate. The primary lesions and intrahepatic metastases of malignant liver tumors have been better demonstrated in the clinical study with the use of various isotope-labeled fibroblast activating protein inhibitors because of their low uptake in liver tissues and high tumor/background ratio, which provides a new method for early diagnosis, precise staging, and radionuclide therapy. In light of this context, a review of the research progress of fibroblast-activating protein inhibitors for the diagnosis of liver malignant tumors is presented.
ISSN:1007-3418
DOI:10.3760/cma.j.cn501113-20230313-00110